Mass balance, routes of excretion, and pharmacokinetics of investigational oral [ 14 C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors

Conclusions Findings suggest that alisertib is eliminated mainly via feces, consistent with hepatic metabolism and biliary excretion of drug-related material. Further investigation of alisertib pharmacokinetics in patients with moderate-severe hepatic impairment is warranted to inform dosing recommendations in these patient populations.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research